Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non–small-cell lung cancer
MJ Edelman, L Hodgson, X Wang… - Journal of Clinical …, 2012 - ascopubs.org
TO THE EDITOR: Groen et al1 recently reported the results of Nederlandse Vereniging voor
Artsen Longziekten en Tuberculose (NVALT)–4, a prospective trial of celecoxib in addition to …
Artsen Longziekten en Tuberculose (NVALT)–4, a prospective trial of celecoxib in addition to …
[HTML][HTML] COX-2 inhibitors in NSCLC: never-ending story or misplaced?
A Martinez-Marti, A Navarro, E Felip - Translational Lung Cancer …, 2018 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 3): S191-S194 tlcr. amegroups. com and retrospective trials (of a total of 2,651 …
(Suppl 3): S191-S194 tlcr. amegroups. com and retrospective trials (of a total of 2,651 …
[PDF][PDF] Did targeted therapy fail cyclooxygenase too?
I Csiki, DH Johnson - Journal of clinical oncology, 2006 - Citeseer
There are considerable preclinical and clinical data showing that cyclooxygenase-2 (COX-2)
plays an important role in the pathogenesis of non–small-cell lung cancers (NSCLC). 1, 2 …
plays an important role in the pathogenesis of non–small-cell lung cancers (NSCLC). 1, 2 …
Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non–small-cell lung cancer with …
MJ Edelman, X Wang, L Hodgson… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with …
HJM Groen, H Sietsma, A Vincent… - Journal of clinical …, 2011 - ascopubs.org
Purpose Cyclooxygenase-2 (COX-2) protein expression in patients with non–small-cell lung
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
cancer (NSCLC) may be not only a prognostic marker but also predictive for COX-2 …
[HTML][HTML] Revisiting the role of COX-2 inhibitor for non-small cell lung cancer
H Yokouchi, K Kanazawa - Translational lung cancer research, 2015 - ncbi.nlm.nih.gov
Accumulating preclinical and clinical studies have shown that cyclooxygenase-2 (COX-2)
inhibitor has some efficacy for non-small cell lung cancer (NSCLC). However, two phase III …
inhibitor has some efficacy for non-small cell lung cancer (NSCLC). However, two phase III …
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
M Gulyas, JSM Mattsson, A Lindgren, L Ek… - Acta …, 2018 - Taylor & Francis
Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …
A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The …
H Groen, MM Hochstenbag, JW van Putten… - Journal of Clinical …, 2009 - ascopubs.org
8005 Background: Cox-2 is overexpressed in NSCLC tumors and has a negative impact on
survival. It is involved in proliferation and angiogenesis. The hypothesis is that celecoxib by …
survival. It is involved in proliferation and angiogenesis. The hypothesis is that celecoxib by …
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non–small cell lung cancer patients …
Abstract Purpose: Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates antitumor
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …
[HTML][HTML] A randomized, placebo-controlled, multicenter, biomarker-selected, Phase 2 study of apricoxib in combination with erlotinib in patients with advanced non …
BJ Gitlitz, E Bernstein, ES Santos, GA Otterson… - Journal of Thoracic …, 2014 - Elsevier
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …